SSXB2 Inhibitors
SSXB2 inhibitors represent a class of chemical compounds that are characterized by their ability to interact with the SSXB2 receptor, a specific molecular target within biological systems. The unique structural features of these inhibitors allow them to bind with high affinity to the receptor, thereby modulating its activity. At the molecular level, SSXB2 inhibitors typically possess a defined scaffold that facilitates their interaction with the receptor's active site or allosteric sites, which can lead to a change in the receptor's conformation and function. The specificity of these inhibitors for the SSXB2 receptor is a result of extensive structure-activity relationship studies that have identified key functional groups and moieties that are critical for high-affinity binding.
Chemically, SSXB2 inhibitors may vary widely in their structure, ranging from small molecules to more complex organic compounds. The design of these inhibitors often involves the incorporation of heterocyclic rings, polar substituents, and various side chains that enhance their affinity for the SSXB2 receptor while also improving their selectivity over other related receptors. The structure of SSXB2 inhibitors is such that they can engage in a range of non-covalent interactions with the receptor, including hydrogen bonding, hydrophobic interactions, and van der Waals forces. These interactions are finely tuned to ensure that the inhibitors can effectively compete with natural ligands or other regulatory molecules that may influence the receptor's activity. The chemical stability, solubility, and overall physicochemical properties of SSXB2 inhibitors are also key considerations in their design, as these factors can influence their behavior and interaction with the SSXB2 receptor.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is a potent phosphoinositide 3-kinase (PI3K) inhibitor that can prevent AKT phosphorylation, thereby reducing SSXB2 activity by limiting the PI3K/AKT pathway, which may contribute to the functional regulation of SSXB2. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is another PI3K inhibitor that suppresses AKT activation. By inhibiting the PI3K/AKT pathway, it subsequently leads to decreased SSXB2 activity as this protein may be downstream of PI3K/AKT signaling. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin specifically inhibits mTORC1, a downstream target of the PI3K/AKT pathway. This inhibition can lead to reduced protein synthesis and potentially lower SSXB2 levels if it is translationally controlled by mTOR signaling. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is a selective inhibitor of MEK, which acts upstream of ERK in the MAPK pathway. This pathway may have cross-talk with SSXB2 activity, and inhibiting MEK could result in decreased signaling through SSXB2. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is a MEK inhibitor similar to PD98059, and it prevents the activation of ERK2. By blocking the MAPK pathway, U0126 could diminish signaling events that lead to the activation of SSXB2. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 inhibits JNK, which is part of the MAPK pathway. JNK inhibition could affect transcription factors that influence SSXB2 expression or activity, thereby reducing its functional activity. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a selective inhibitor of p38 MAPK. Inhibition of p38 may reduce SSXB2 activity by preventing phosphorylation events that could be necessary for SSXB2 function. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $92.00 $223.00 | 30 | |
PP2 is a selective inhibitor of Src family kinases. Src kinases can be involved in various signaling pathways that potentially regulate SSXB2 activity. Inhibiting Src kinase activity could therefore attenuate SSXB2 signaling. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
Dasatinib broadly inhibits Src family kinases and BCR-ABL. By targeting these kinases, Dasatinib could reduce the phosphorylation of substrates involved in SSXB2 signaling, leading to decreased SSXB2 activity. | ||||||
GW 5074 | 220904-83-6 | sc-200639 sc-200639A | 5 mg 25 mg | $106.00 $417.00 | 10 | |
GW5074 is an inhibitor of RAF1 kinase, which is upstream of the MAPK/ERK pathway. By inhibiting RAF1, GW5074 could limit the activation of downstream targets that are involved in the regulation of SSXB2. | ||||||